TITLE

An Unexpected Reprieve

AUTHOR(S)
Whitford, Ben
PUB. DATE
September 2005
SOURCE
Newsweek (Pacific Edition);9/12/2005 (Pacific Edition), Vol. 146 Issue 11, p48
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Discusses new treatments for cystic fibrosis (CF) which can extend patients' life spans from months to years and from years to decades. Background on the lethal genetic disorder; The extended life span of today's CF patients which stems not from a single breakthrough but from a stream of minor innovations; Various weapons doctors use in the battle against CF; Profiles of adult CF patients who were not expected to live; Genetic testing for CF.
ACCESSION #
18241098

 

Related Articles

  • An Unexpected Reprieve. Whitford, Ben // Newsweek (Atlantic Edition);9/12/2005 (Atlantic Edition), Vol. 146 Issue 11, p54 

    Discusses new treatments for cystic fibrosis (CF) which can extend patients' life spans from months to years and from years to decades. Background on the lethal genetic disorder; The extended life span of today's CF patients which stems not from a single breakthrough but from a stream of minor...

  • An Unexpected Reprieve. Whitford, Ben // Newsweek;9/12/2005, Vol. 146 Issue 11, p64 

    Discusses new treatments for cystic fibrosis (CF) which can extend patients' life spans from months to years and from years to decades. Background on the lethal genetic disorder; The extended life span of today's CF patients which stems not from a single breakthrough but from a stream of minor...

  • Gene therapy in cystic fibrosis. Armstrong, David K.; Cunningham, Steve; Davies, Jane C.; Alton, Eric W. F. W. // Archives of Disease in Childhood;May2014, Vol. 99 Issue 5, p465 

    The principal cause of morbidity and mortality in cystic fibrosis (CF) is pulmonary disease, so the focus of new treatments in this condition is primarily targeted at the lungs. Since the cloning of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene in 1989, there has been...

  • Novel agents in cystic fibrosis. Storey, Shane; Wald, Graeme // Nature Reviews Drug Discovery;Jul2008, Vol. 7 Issue 7, p555 

    The article provides information on several therapeutic agents that improve the treatment of cystic fibrosis. It states that Pulmozyme drug from Genentech Inc. is a recombinant human DNase, which reduces mucus viscosity in the lungs. Moreover, it notes that the hyperosmolar agent Bronchitol is...

  • The Use of Human Deoxyribonuclease (rhDNase) in the Management of Cystic Fibrosis. Suri, Ranjan // BioDrugs;2005, Vol. 19 Issue 3, p135 

    In patients with cystic fibrosis (CF), the poor clearance of airway secretions promotes recurrent cycles of pulmonary infection and inflammation. In recent years, novel drugs have been developed to alter the properties of the secretions in an attempt to aid chest physiotherapy in improving...

  • The facts on cystic fibrosis. Norvell, Candyce // Current Health 2;May95, Vol. 21 Issue 9, p22 

    Presents facts on cystic fibrosis (CF), a fatal genetic disease. Transmission of defective gene from both parents; Diagnoses of CF in babies; Symptoms; Sweat test; Treatments; Gene therapy.

  • Doorway to a Cure. TRIVEDI, BIJAL P. // Discover;Sep2013, Vol. 34 Issue 7, p42 

    The article discusses the Cystic Fibrosis Foundation (CFF), a nonprofit organization which has provided financing to biotechnology companies to discover a cure for cystic fibrosis (CF), a genetic disorder which affects the lungs. Topics include fundraising by CFF for the drug research and...

  • Inhaled hypertonic saline in cystic fibrosis.  // Archives of Disease in Childhood;Jun2006, Vol. 91 Issue 6, p468 

    The article looks at two studies on the effectiveness of regular inhalation of hypertonic saline in young patients with cystic fibrosis. In Australia, 164 patients inhaled saline twice a day for 48 weeks. In the United States, 24 patients inhaled nebulized hypertonic saline four times daily for...

  • Treatment of Cystic Fibrosis with Penicillamine. A Hypothesis Based on the Physiology of Mucus and Sweat. Bucay, Alberto Halabe // Pediatrics & Therapeutics;2012, Vol. 2 Issue 4, Special section p1 

    The article discusses the possibility of treating cystic fibrosis with penicillamine. It describes cystic fibrosis as an inherited disease characterized by increased production of mucus in the lungs and digestive system and production of altered sweat. Trace metals that can be found in the mucus...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics